Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

369 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.
Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM. Thanarajasingam G, et al. Among authors: gisselbrecht c. Lancet Haematol. 2018 Nov;5(11):e563-e598. doi: 10.1016/S2352-3026(18)30051-6. Epub 2018 Jun 18. Lancet Haematol. 2018. PMID: 29907552 Free PMC article. Review.
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.
Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gormley N, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Kwong YL, Little RF, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Nair A, Nastoupil L, Robertson K, Sidana S, Smedby KE, Sonneveld P, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Seymour JF, Habermann TM. Thanarajasingam G, et al. Among authors: gisselbrecht c. Lancet Haematol. 2022 May;9(5):e374-e384. doi: 10.1016/S2352-3026(22)00045-X. Lancet Haematol. 2022. PMID: 35483398 Free PMC article. Review.
Reducing Bureaucracy in Clinical Research: A Call for Action.
Gribben J, Macintyre E, Sonneveld P, Doorduijn J, Gisselbrecht C, Jäger U, Le Gouill S, Rule S, Dreyling M. Gribben J, et al. Among authors: gisselbrecht c. Hemasphere. 2020 Feb 26;4(2):e352. doi: 10.1097/HS9.0000000000000352. eCollection 2020 Apr. Hemasphere. 2020. PMID: 32309789 Free PMC article. No abstract available.
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
Tzogani K, van Hennik P, Walsh I, De Graeff P, Folin A, Sjöberg J, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. Tzogani K, et al. Among authors: gisselbrecht c. Oncologist. 2018 May;23(5):631-636. doi: 10.1634/theoncologist.2017-0301. Epub 2017 Nov 30. Oncologist. 2018. PMID: 29192015 Free PMC article. Review.
Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Ali S, Moreau A, Melchiorri D, Camarero J, Josephson F, Olimpier O, Bergh J, Karres D, Tzogani K, Gisselbrecht C, Pignatti F. Ali S, et al. Among authors: gisselbrecht c. Oncologist. 2020 Apr;25(4):e709-e715. doi: 10.1634/theoncologist.2019-0559. Epub 2019 Nov 14. Oncologist. 2020. PMID: 32297447 Free PMC article.
European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Tzogani K, Yu Y, Meulendijks D, Herberts C, Hennik P, Verheijen R, Wangen T, Dahlseng Håkonsen G, Kaasboll T, Dalhus M, Bolstad B, Salmonson T, Gisselbrecht C, Pignatti F. Tzogani K, et al. Among authors: gisselbrecht c. ESMO Open. 2019 Nov;4(6):e000606. doi: 10.1136/esmoopen-2019-000606. ESMO Open. 2019. PMID: 32392175 Free PMC article. Review.
EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma.
Papadouli I, Mueller-Berghaus J, Beuneu C, Ali S, Hofner B, Petavy F, Tzogani K, Miermont A, Norga K, Kholmanskikh O, Leest T, Schuessler-Lenz M, Salmonson T, Gisselbrecht C, Garcia JL, Pignatti F. Papadouli I, et al. Among authors: gisselbrecht c. Oncologist. 2020 Oct;25(10):894-902. doi: 10.1634/theoncologist.2019-0646. Epub 2020 Apr 27. Oncologist. 2020. PMID: 32339368 Free PMC article. Review.
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Tzogani K, Penninga E, Schougaard Christiansen ML, Hovgaard D, Sarac SB, Camarero Jimenez J, Garcia I, Lafuente M, Sancho-López A, Salmonson T, Gisselbrecht C, Pignatti F. Tzogani K, et al. Among authors: gisselbrecht c. Oncologist. 2018 May;23(5):594-602. doi: 10.1634/theoncologist.2017-0328. Epub 2018 Jan 25. Oncologist. 2018. PMID: 29371479 Free PMC article. Clinical Trial.
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
Tzogani K, Camarero Jiménez J, Garcia I, Sancho-López A, Martin M, Moreau A, Demolis P, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. Tzogani K, et al. Among authors: gisselbrecht c. Oncologist. 2017 Nov;22(11):1339-1346. doi: 10.1634/theoncologist.2017-0184. Epub 2017 Sep 21. Oncologist. 2017. PMID: 28935772 Free PMC article. Clinical Trial.
369 results